Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus OVCON 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus OVCON 50.
NORTREL 0.5/35-28 vs OVCON-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone and ethinyl estradiol are a combination hormonal contraceptive. Norethindrone suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and enhances the contraceptive effect by inhibiting gonadotropin secretion.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus and endometrial lining.
1 tablet orally once daily for 28 days (21 active tablets containing 0.5 mg norethindrone and 35 mcg ethinyl estradiol, followed by 7 placebo tablets).
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days followed by 7 days of placebo or no tablets.
None Documented
None Documented
Norethindrone: 7.2-9.2 hours; Ethinyl estradiol: 13-27 hours. Clinical context: Steady state reached in 5-7 days; half-life supports once-daily dosing.
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 7-20 hours. Clinical context: Steady-state reached within 5-7 days; half-life allows once-daily dosing with stable contraceptive efficacy.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites; <5% unchanged.
Renal: 40-60% (metabolites, primarily glucuronide conjugates; <1% unchanged). Fecal: 30-50% (via biliary elimination).
Category C
Category C
Oral Contraceptive
Oral Contraceptive